Holen Sie sich die Stockscreener-App
22.92
3.71%
0.82
Handel nachbörslich:
22.86
-0.06
-0.26%
Schlusskurs vom Vortag:
$22.10
Offen:
$21.43
24-Stunden-Volumen:
3.23M
Relative Volume:
1.27
Marktkapitalisierung:
$3.67B
Einnahmen:
$295.41M
Nettoeinkommen (Verlust:
$-49.64M
KGV:
-70.01
EPS:
-0.3274
Netto-Cashflow:
$-29.54M
1W Leistung:
+8.83%
1M Leistung:
+36.59%
6M Leistung:
+30.82%
1J Leistung:
+118.29%
1-Tages-Spanne:
$21.36
$23.02
1-Wochen-Bereich:
$20.46
$23.15
52-Wochen-Spanne:
$9.9551
$23.15
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
22.92 | 3.54B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Adaptive Biotechnologies CPO Lo reports $2.39m stock sale - Investing.com
Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com - Investing.com Canada
Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares - Stock Titan
Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT) - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 22.81 USD - Investing.com
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run - Yahoo Finance
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run - The Motley Fool
Adaptive Biotechnologies to report Q2 2026 results on July 29 - scanx.trade
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 - The Manila Times
ADPT Maintained by Morgan Stanley -- Price Target Raised to $20. - GuruFocus
Adaptive Biotechnologies sets July 29 results call after market close - Stock Titan
Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock By Investing.com - Investing.com Nigeria
Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock - Investing.com
Form 4 Adaptive Biotechnologies Corp For: 7 July By Investing.com - Investing.com South Africa
CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan - Stock Titan
Enterprise value to EBIT forward of Adaptive Biotechnologies Corp. – DUS:1HM - TradingView
Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock - Investing.com
Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock - Investing.com
Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock By Investing.com - Investing.com Nigeria
Form 4 Adaptive Biotechnologies Corp For: 6 July By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (ADPT) CPO trades 95,842 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 487 shares under 10b5-1 plan - Stock Titan
Price to sales forward of Adaptive Biotechnologies Corp. – DUS:1HM - TradingView
Francis Lo plans ADPT share sales (NASDAQ: ADPT) under Form 144 - Stock Titan
ETFs Investing in Adaptive Biotechnologies Corp. Stocks - TradingView
Harlan Robins sells 116,160 ADPT shares (ADPT) per Form 144 filing - Stock Titan
ADPTAdaptive Biotechnologies Corp Earnings - Finviz
ADPT Stock Price, Quote & Chart - ChartMill
ADPT (NASDAQ: ADPT) insider sold shares via 10b5-1 plan in June 2026 - Stock Titan
Form 4 Adaptive Biotechnologies Corp For: 29 June By Investing.com - Investing.com Nigeria
Adaptive biotechnologies CCO Sharon Benzeno sells over $3.5m in stock - Investing.com South Africa
Form 4 Adaptive Biotechnologies Corp For: 30 June By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (ADPT) CCO trades shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies chief commercial officer sells $102,500 in stock - Investing.com
Adaptive Biotechnologies director Michelle Griffin sells $1.05m stock - Investing.com
Adaptive Biotechnologies director Michelle Griffin sells $1.05m stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies chief commercial officer sells $102,500 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (ADPT) CCO sells 5,000 shares under 10b5-1 plan - Stock Titan
Director at Adaptive Biotechnologies (NASDAQ: ADPT) exercises options and sells shares - Stock Titan
Form 144 ADAPTIVE BIOTECHNOLOGIES CORPORATION For: 29 June By Investing.com - Investing.com South Africa
Insider sells shares under 10b5-1 plan — ADPT (NASDAQ: ADPT) - Stock Titan
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):